The Future of Small Molecule In Vivo Activated Cell Therapy: Modulation of Tregs in the Body
Time: 12:00 pm
day: Day Two AM Cell-Based Approaches
Details:
- AZD1656 is a specific activator of glucokinase; but not hexokinase (the latter is used by T effector lymphocytes for migration)
- A randomised blinded placebo-controlled trial of this drug in diabetic patients with Covid 19 significantly decreased death and time in hospital in the treated group. This trial was undertaken by the speaker and his team. New immunology data from this human study will be presented
- This approach will be tested in several autoimmune diseases
